Paper Details

  1. Home
  2. Paper Details

Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.

Author: AlmarjanAmjaad Ibrahim, AlmarjanSara Abdulaziz, MasoudAhmed Taher

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Sacubitril/valsartan, a drug with neprilysin inhibition and angiotensin receptor-blocking properties, is expected to have strong antihypertensive effects. However, there is limited evidence to compare its safety and efficacy with olmesartan in patients with hypertension.
Paper Details　
Original Abstract of the Article :
Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40292-023-00572-7

データ提供：米国国立医学図書館（NLM）

Sacubitril/Valsartan: A New Oasis for Essential Hypertension?

Essential hypertension, a condition characterized by persistently high blood pressure, affects millions worldwide. This systematic review and meta-analysis delved into the vast desert of research to compare the safety and efficacy of sacubitril/valsartan (LCZ696) with olmesartan, both commonly used antihypertensive medications. Sacubitril/valsartan combines neprilysin inhibition and angiotensin receptor-blocking properties, making it a promising candidate for managing hypertension. The review found that sacubitril/valsartan demonstrated strong antihypertensive effects, but there wasn't sufficient evidence to definitively conclude its superiority over olmesartan in patients with hypertension. However, the review highlights the potential of sacubitril/valsartan as a valuable addition to the arsenal of antihypertensive treatments.

A New Approach: Exploring the Benefits of Sacubitril/Valsartan

This review encourages further research to fully assess the efficacy and safety of sacubitril/valsartan in comparison to olmesartan. The study's findings suggest that sacubitril/valsartan holds promise as a potent antihypertensive agent, potentially offering new therapeutic options for individuals with hypertension.

A Journey Through the Desert of Hypertension

This review highlights the ongoing search for better and safer treatment options for hypertension. The findings suggest that sacubitril/valsartan may offer a promising new approach, but further research is needed to determine its optimal role in managing hypertension. As we continue to explore the vast desert of hypertension research, we may discover even more effective and personalized treatments for this common condition.

Dr.Camel's Conclusion

This review offers a glimpse into the potential of sacubitril/valsartan as a promising new treatment for essential hypertension, but further research is needed to definitively establish its benefits and risks. The quest for effective hypertension treatments continues, and this review serves as a reminder of the ongoing efforts to improve the lives of those affected by this condition.

Date :
  1. Date Completed 2023-06-02
  2. Date Revised 2023-08-04
Further Info :

Pubmed ID

37017901

DOI: Digital Object Identifier

10.1007/s40292-023-00572-7

Related Literature

Article Analysis
・Side Effects of valsartan・Effects of valsartan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.